Effects of oral duloxetine on reduction of symptoms of peripheral neuropathy

Comparison of the therapeutic effects of oral duloxetine alone and with combination gel on reduction of symptoms of chemotherapy-induced peripheral neuropathy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110514006480N16

Enrollment

Registered

2018-08-01

Start date

2018-08-01

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced peripheral neuropathy.

Interventions

Intervention 1: Intervention group 1: Patients will receive oral duloxetine 30 mg once daily (in the morning) along with topical placebo gel 1.3 g twice (morning and night) a day. Intervention 2: Inte

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients under treatment with neurotoxic chemotherapy drugs, Which have symptoms of peripheral neuropathy Normal blood calcium and magnesium levels

Exclusion criteria

Exclusion criteria: Having diabetes and other causes of peripheral neuropathy History of severe hypersensitivity to duloxetine

Design outcomes

Primary

Measure	Time frame
Mean scores of peripheral neuropathy symptoms in LQ-CIPN20 questionnaire. Timepoint: Before the intervention, 4 week after treatment with duloxetine. Method of measurement: LQ-CIPN20 questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Roholla Masoumi

Shahre-kord University of Medical Sciences

masomi@skums.ac.ir+98 38 1226 4825

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026